| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Yadanzioside I targets viral replication mechanisms, specifically those of tobacco mosaic virus (TMV). As a quassinoid, it may also target other viral pathogens. The compound is an anti-infection agent. Its mechanism of action likely involves interference with viral replication or host-virus interactions.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Yadanzioside I exhibits potent antiviral activity against TMV with an IC50 of 4.22 μM. This activity demonstrates the compound's direct antiviral effects. The compound is a potent anti-TMV quassinoid.
|
| ln Vivo |
Yadanzioside I has not been extensively characterized for in vivo activity. As an antiviral quassinoid, it may have potential for in vivo evaluation in plant or animal models of viral infection. The compound's potent anti-TMV activity suggests it could be effective against other viruses as well. Further studies are required to establish its in vivo efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
The cell-free assay for Yadanzioside I involves measuring its antiviral activity against tobacco mosaic virus. The compound is incubated with TMV particles or infected plant material, and viral replication is assessed by measuring viral RNA or protein levels. The IC50 of 4.22 μM is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for Yadanzioside I involve culturing virus-infected cells and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Antiviral activity is assessed by measuring viral replication using qRT-PCR, plaque assays, or by measuring viral protein expression. The compound's effects on cell viability are assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
There is no established animal experimental protocol for Yadanzioside I specifically. As a quassinoid with antiviral activity, the compound could potentially be evaluated in animal models of viral infection. Typical studies involve administration of the compound to mice via intraperitoneal or oral routes. Viral load, tissue damage, and survival would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Yadanzioside I have not been extensively reported. As a glycosylated quassinoid with a molecular weight of 642.60 g/mol, the compound would be expected to have limited oral bioavailability and may require parenteral administration. The compound is typically stored at 2-8°C, protected from light and desiccated. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Yadanzioside I is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a quassinoid with antiviral activity, it may have effects on normal cells as well as virus-infected cells. The compound is typically stored at 2-8°C. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
It has been reported that methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-acetoxy-15,16-dihydroxy-9,13-dimethyl-4,11-dioxo-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxecyclo-2-yl]oxy-5,18-dioxapentane[12.5.0.01,6.02,17.08,13]nonadecan-9-en-17-carboxylic acid ester exists in the Brucea javanica, and relevant data are available.
Yadanzioside I is a research-grade natural product supplied for antiviral research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a potent anti-TMV quassinoid from Brucea javanica with an IC50 of 4.22 μM. It has strong antiviral activity. This product is intended for research use only. |
| Molecular Formula |
C29H38O16
|
|---|---|
| Molecular Weight |
642.602
|
| Exact Mass |
642.215
|
| CAS # |
99132-95-3
|
| PubChem CID |
21636148
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.4
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1330
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
CC1=C(C(=O)CC2(C1CC3C45C2C(C(C(C4C(C(=O)O3)OC(=O)C)(OC5)C(=O)OC)O)O)C)OC6C(C(C(C(O6)CO)O)O)O
|
| InChi Key |
QVXFIBXCQCYPLP-BBIBOMAQSA-N
|
| InChi Code |
InChI=1S/C29H38O16/c1-9-11-5-14-28-8-41-29(26(39)40-4,22(28)20(24(38)44-14)42-10(2)31)23(37)18(36)21(28)27(11,3)6-12(32)19(9)45-25-17(35)16(34)15(33)13(7-30)43-25/h11,13-18,20-23,25,30,33-37H,5-8H2,1-4H3/t11-,13+,14+,15+,16-,17+,18+,20+,21+,22+,23-,25-,27-,28+,29-/m0/s1
|
| Chemical Name |
methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-acetyloxy-15,16-dihydroxy-9,13-dimethyl-4,11-dioxo-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5562 mL | 7.7809 mL | 15.5618 mL | |
| 5 mM | 0.3112 mL | 1.5562 mL | 3.1124 mL | |
| 10 mM | 0.1556 mL | 0.7781 mL | 1.5562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
